首页> 美国卫生研究院文献>Frontiers in Immunology >Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8+ T-Regulatory Cells that Suppress SIV-Positive CD4+ T-Cell Activation and Prevent SIV Infection in the Macaque Model
【2h】

Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8+ T-Regulatory Cells that Suppress SIV-Positive CD4+ T-Cell Activation and Prevent SIV Infection in the Macaque Model

机译:包含灭活病毒颗粒和细菌佐剂的粘膜SIV疫苗可诱导CD8 + T调节细胞抑制SIV阳性CD4 + T细胞活化并在猕猴模型中预防SIV感染。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A new paradigm of mucosal vaccination against human immunodeficiency virus (HIV) infection has been investigated in the macaque model. A vaccine consisting of inactivated simian immunodeficiency virus (SIV)mac239 particles together with a living bacterial adjuvant (either the Calmette and Guerin bacillus, Lactobacillus plantarum or Lactobacillus rhamnosus) was administered to macaques via the vaginal or oral/intragastric route. In contrast to all established human and veterinary vaccines, these three vaccine regimens did not elicit SIV-specific antibodies nor cytotoxic T-lymphocytes but induced a previously unrecognized population of non-cytolytic MHCIb/E-restricted CD8+ T-regulatory cells that suppressed the activation of SIV-positive CD4+ T-lymphocytes. SIV reverse transcription was thereby blocked in inactivated CD4+ T-cells; the initial burst of virus replication was prevented and the vaccinated macaques were protected from a challenge infection. For 3–14 months after intragastric immunization, 24 macaques were challenged intrarectally with a high dose of SIVmac239 or with the heterologous strain SIV B670 (both strains grown on macaques PBMC). Twenty-three of these animals were found to be protected for up to 48 months while all 24 control macaques became infected. This protective effect against SIV challenge together with the concomitant identification of a robust ex vivo correlate of protection suggests a new approach for developing an HIV vaccine in humans. The induction of this new class of CD8+ T-regulatory cells could also possibly be used therapeutically for suppressing HIV replication in infected patients and this novel tolerogenic vaccine paradigm may have potential applications for treating a wide range of immune disorders and is likely to may have profound implications across immunology generally.
机译:在猕猴模型中,已经研究了针对人类免疫缺陷病毒(HIV)感染的粘膜疫苗接种的新范例。通过灭活的猿猴免疫缺陷病毒(SIV)mac239颗粒和活细菌佐剂(卡介苗和Guerin芽孢杆菌,植物乳杆菌或鼠李糖乳杆菌)组成的疫苗经阴道或口服/胃内途径给药于猕猴。与所有已建立的人和兽用疫苗相比,这三种疫苗方案均未引发SIV特异性抗体或细胞毒性T淋巴细胞,但却诱导了先前未被认识的非细胞溶解性MHCIb / E限制性CD8 + 抑制SIV阳性CD4 + T淋巴细胞活化的T调节细胞。从而在灭活的CD4 + T细胞中阻断了SIV逆转录;防止了病毒复制的最初爆发,并且保护了接种过的猕猴免受攻击性感染。胃内免疫后3-14个月,用高剂量的SIVmac239或异源菌株SIV B670(均在猕猴PBMC上生长)对24只猕猴进行直肠内攻击。发现其中的23只动物受到保护的时间长达48个月,而所有24只对照猕猴都受到了感染。这种针对SIV攻击的保护作用,以及随之而来的对稳健的离体保护相关物质的鉴定,提出了一种开发人类HIV疫苗的新方法。这种新型的CD8 + T调节细胞的诱导也可能在治疗上用于抑制感染患者的HIV复制,这种新型的致耐受性疫苗范式可能在治疗广泛的免疫方面具有潜在的应用前景疾病,通常可能会对整个免疫学产生深远的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号